Trial · NCT03928184
Adverse events90
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 90
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arthralgia | Musculoskeletal and connective tissue disorders | 0.07 mg Lorecivivint | 19 | 249 | 21 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Vehicle | 17 | 252 | 19 |
| other | Urinary tract infection | Infections and infestations | 0.07 mg Lorecivivint | 16 | 249 | 17 |
| other | Urinary tract infection | Infections and infestations | Vehicle | 13 | 252 | 13 |
| other | Back pain | Musculoskeletal and connective tissue disorders | 0.07 mg Lorecivivint | 13 | 249 | 14 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Vehicle | 8 | 252 | 10 |
| other | COVID-19 | Infections and infestations | 0.07 mg Lorecivivint | 11 | 249 | 11 |
| other | COVID-19 | Infections and infestations | Vehicle | 7 | 252 | 7 |
| other | Joint swelling | Musculoskeletal and connective tissue disorders | 0.07 mg Lorecivivint | 7 | 249 | 8 |
| other | Joint swelling | Musculoskeletal and connective tissue disorders | Vehicle | 4 | 252 | 4 |
| other | Nasopharyngitis | Infections and infestations | 0.07 mg Lorecivivint | 7 | 249 | 7 |
| other | Nasopharyngitis | Infections and infestations | Vehicle | 4 | 252 | 6 |
| other | Headache | Nervous system disorders | 0.07 mg Lorecivivint | 6 | 249 | 11 |
| other | Headache | Nervous system disorders | Vehicle | 10 | 252 | 13 |
| other | Upper respiratory tract infection | Infections and infestations | 0.07 mg Lorecivivint | 6 | 249 | 6 |
| other | Upper respiratory tract infection | Infections and infestations | Vehicle | 5 | 252 | 5 |
| other | Sciatica | Nervous system disorders | 0.07 mg Lorecivivint | 5 | 249 | 5 |
| other | Sciatica | Nervous system disorders | Vehicle | 2 | 252 | 2 |
| other | Contusion | Injury, poisoning and procedural complications | 0.07 mg Lorecivivint | 5 | 249 | 5 |
| other | Contusion | Injury, poisoning and procedural complications | Vehicle | 5 | 252 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03928184/events